Tous Actualités
Suivre
Abonner Intercell AG

Intercell AG

euro adhoc: Intercell AG
other
Intercell receives milestone payment triggered by initiation of further clinical trial for Flu vaccine with IC31

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
Company Information
13.06.2008
» Further clinical trial for a seasonal flu vaccine containing 
Intercell´s   adjuvant IC31® being initiated
» Intercell will be entitled to receive EUR 2 m milestone payment 
upon   the vaccination of the first human subject in the  clinical 
trial
Vienna (Austria), June 13, 2008 - Intercell AG (VSE: ICLL) today 
announced progress in its collaboration with Novartis to develop an 
improved Influenza vaccine. Novartis now has initiated its in-house 
development program with clinical trials designed to demonstrate 
safety and immunogenicity of a seasonal Influenza vaccine adjuvanted 
with IC31®. This triggers a milestone payment of EUR 2 m to 
Intercell. As part of the agreement between Novartis and Intercell, 
signed in July 2007, Novartis has an exclusive license for 
development of Intercell's IC31® adjuvant in novel influenza 
vaccines. As announced in February 2008 Intercell completed an 
initial Phase I clinical trial of the company's adjuvant IC31® in 
combination with the seasonal, trivalent influenza vaccine Agrippal® 
from Novartis. The IC31® adjuvanted vaccine showed an excellent 
safety and tolerability profile, which was comparable to the 
non-adjuvanted standard vaccine. Furthermore in all study groups 
vaccination with the test vaccine led to the induction of virus 
specific T-cells and protective levels of antibody responses against 
the three included influenza strains.
Gerd Zettlmeissl, CEO of Intercell, commented: "Intercell's IC31® has
shown excellent preclinical data and an encouraging profile in first 
trials in humans and we are confident that an influenza vaccine 
formulated with IC31® now further developed by Novartis has potential
to become a next generation vaccine."
About IC31®
Vaccines, based on antigens alone, are not sufficient to provide full
protection. Adjuvants are needed to educate the immune system to 
recognize and eliminate the pathogens efficiently. IC31® is an 
adjuvant that induces T-cell and B-cell responses by using a unique 
synthetic formulation which combines the immunostimulating properties
of an anti-microbial peptide, KLK, and an immunostimulatory 
oligodeoxynucleotide, ODN1a. The two component solution can be simply
mixed with antigens; no conjugation is required. Intercell currently 
uses IC31® in collaborations with a number of global vaccine 
companies and biotech companies. These collaborations include amongst
others the development of a tuberculosis vaccine in Phase I clinical 
trials, which has been partnered with the Danish Statens Serum 
Institut and Sanofi Pasteur.
end of announcement                               euro adhoc

Further inquiry note:

Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303
lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market

Plus de actualités: Intercell AG
Plus de actualités: Intercell AG